Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser SI, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A.
Doyle A, et al.
Scand J Gastroenterol. 2016 Aug;51(8):979-85. doi: 10.3109/00365521.2016.1166518. Epub 2016 May 10.
Scand J Gastroenterol. 2016.
PMID: 27161568
CONCLUSIONS: Survival in patients with Child-Pugh C liver function or advanced functional impairment treated with sorafenib is poor and thus routine use of this agent in these patients does not appear justified, particularly given the high rate of adverse effects. ...
CONCLUSIONS: Survival in patients with Child-Pugh C liver function or advanced functional impairment treated with sorafenib is poor a …